Teyi Pharmaceutical Group Co Ltd
Teyi Pharmaceutical Group Co.,Ltd engages in the research and development, production, and sale of Chinese patented medicines, pharmaceutical preparations, raw materials, and products in the People's Republic of China. The company provides cough and phlegm, kidney, anti-infection, cardiovascular and cerebrovascular, and digestive system drugs, as well as pediatrics, dermatology, tuberculosis, res… Read more
Teyi Pharmaceutical Group Co Ltd (002728) - Net Assets
Latest net assets as of September 2025: CN¥1.80 Billion CNY
Based on the latest financial reports, Teyi Pharmaceutical Group Co Ltd (002728) has net assets worth CN¥1.80 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.22 Billion) and total liabilities (CN¥417.67 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.80 Billion |
| % of Total Assets | 81.19% |
| Annual Growth Rate | 20.84% |
| 5-Year Change | 63.35% |
| 10-Year Change | 119.44% |
| Growth Volatility | 29.65 |
Teyi Pharmaceutical Group Co Ltd - Net Assets Trend (2009–2024)
This chart illustrates how Teyi Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Teyi Pharmaceutical Group Co Ltd (2009–2024)
The table below shows the annual net assets of Teyi Pharmaceutical Group Co Ltd from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.76 Billion | -12.22% |
| 2023-12-31 | CN¥2.01 Billion | +43.30% |
| 2022-12-31 | CN¥1.40 Billion | +11.21% |
| 2021-12-31 | CN¥1.26 Billion | +16.78% |
| 2020-12-31 | CN¥1.08 Billion | -6.30% |
| 2019-12-31 | CN¥1.15 Billion | +3.76% |
| 2018-12-31 | CN¥1.11 Billion | +6.56% |
| 2017-12-31 | CN¥1.04 Billion | +17.63% |
| 2016-12-31 | CN¥886.57 Million | +10.23% |
| 2015-12-31 | CN¥804.30 Million | +9.33% |
| 2014-12-31 | CN¥735.64 Million | +110.10% |
| 2013-12-31 | CN¥350.14 Million | +22.71% |
| 2012-12-31 | CN¥285.34 Million | +26.53% |
| 2011-12-31 | CN¥225.51 Million | +32.02% |
| 2010-12-31 | CN¥170.81 Million | +65.55% |
| 2009-12-31 | CN¥103.18 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Teyi Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2202.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥353.49 Million | 20.03% |
| Common Stock | CN¥512.21 Million | 29.02% |
| Other Comprehensive Income | CN¥150.23 Million | 8.51% |
| Other Components | CN¥749.00 Million | 42.44% |
| Total Equity | CN¥1.76 Billion | 100.00% |
Teyi Pharmaceutical Group Co Ltd Competitors by Market Cap
The table below lists competitors of Teyi Pharmaceutical Group Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Investis Holding SA
SW:IREN
|
$450.20 Million |
|
DOM DEVELOPMENT SE.A.ZY 1
F:6WV
|
$450.29 Million |
|
Tinexta S.p.A.
LSE:0RIW
|
$450.40 Million |
|
Procter & Gamble Health Limited
NSE:PGHL
|
$450.44 Million |
|
SIPEF SA (POST SPLIT)
F:BZ3
|
$450.18 Million |
|
Luyan Pharma Co Ltd
SHE:002788
|
$450.11 Million |
|
Chongqing Shunbo Aluminum Co Ltd
SHE:002996
|
$449.92 Million |
|
The Hongkong and Shanghai Hotels Limited
F:HSG
|
$449.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Teyi Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,010,681,910 to 1,764,933,238, a change of -245,748,672 (-12.2%).
- Net income of 20,495,003 contributed positively to equity growth.
- Dividend payments of 182,307,116 reduced retained earnings.
- Share repurchases of 93,856,250 reduced equity.
- Other comprehensive income increased equity by 143,919,747.
- Other factors decreased equity by 134,000,056.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥20.50 Million | +1.16% |
| Dividends Paid | CN¥182.31 Million | -10.33% |
| Share Repurchases | CN¥93.86 Million | -5.32% |
| Other Comprehensive Income | CN¥143.92 Million | +8.15% |
| Other Changes | CN¥-134.00 Million | -7.59% |
| Total Change | CN¥- | -12.22% |
Book Value vs Market Value Analysis
This analysis compares Teyi Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.22x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 20.74x to 3.22x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | CN¥0.54 | CN¥11.10 | x |
| 2010-12-31 | CN¥0.84 | CN¥11.10 | x |
| 2011-12-31 | CN¥1.07 | CN¥11.10 | x |
| 2012-12-31 | CN¥1.36 | CN¥11.10 | x |
| 2013-12-31 | CN¥1.66 | CN¥11.10 | x |
| 2014-12-31 | CN¥3.08 | CN¥11.10 | x |
| 2015-12-31 | CN¥2.90 | CN¥11.10 | x |
| 2016-12-31 | CN¥3.14 | CN¥11.10 | x |
| 2017-12-31 | CN¥3.71 | CN¥11.10 | x |
| 2018-12-31 | CN¥3.98 | CN¥11.10 | x |
| 2019-12-31 | CN¥4.03 | CN¥11.10 | x |
| 2020-12-31 | CN¥6.52 | CN¥11.10 | x |
| 2021-12-31 | CN¥6.06 | CN¥11.10 | x |
| 2022-12-31 | CN¥4.50 | CN¥11.10 | x |
| 2023-12-31 | CN¥4.37 | CN¥11.10 | x |
| 2024-12-31 | CN¥3.44 | CN¥11.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Teyi Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.16%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.98%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 1.36x
- Recent ROE (1.16%) is below the historical average (15.26%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 23.36% | 11.92% | 1.07x | 1.84x | CN¥13.78 Million |
| 2010 | 28.09% | 19.13% | 0.99x | 1.48x | CN¥30.90 Million |
| 2011 | 30.91% | 22.84% | 1.08x | 1.26x | CN¥47.14 Million |
| 2012 | 27.54% | 23.06% | 0.88x | 1.36x | CN¥50.04 Million |
| 2013 | 23.01% | 23.50% | 0.76x | 1.30x | CN¥45.54 Million |
| 2014 | 10.90% | 23.26% | 0.42x | 1.12x | CN¥6.63 Million |
| 2015 | 10.08% | 15.70% | 0.32x | 1.99x | CN¥675.46K |
| 2016 | 10.69% | 14.45% | 0.41x | 1.81x | CN¥6.12 Million |
| 2017 | 10.20% | 15.48% | 0.36x | 1.85x | CN¥2.06 Million |
| 2018 | 14.00% | 17.58% | 0.43x | 1.86x | CN¥44.43 Million |
| 2019 | 14.89% | 18.64% | 0.41x | 1.96x | CN¥56.41 Million |
| 2020 | 4.06% | 6.93% | 0.28x | 2.09x | CN¥-64.23 Million |
| 2021 | 10.06% | 16.74% | 0.37x | 1.64x | CN¥748.41K |
| 2022 | 12.70% | 20.10% | 0.35x | 1.81x | CN¥37.89 Million |
| 2023 | 12.59% | 23.72% | 0.42x | 1.25x | CN¥52.11 Million |
| 2024 | 1.16% | 2.98% | 0.29x | 1.36x | CN¥-156.00 Million |
Industry Comparison
This section compares Teyi Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Teyi Pharmaceutical Group Co Ltd (002728) | CN¥1.80 Billion | 23.36% | 0.23x | $450.20 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |